ETFs Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:01:51 2025-06-24 EDT			5-day change	1st Jan Change
372.80 ^DKK	+1.14%		-1.46%	-48.06%

06-19	Zealand Pharma A/S(CPSE:ZEAL) dropped from OMX Nordic 40 Index	CI
06-18	Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	RE

ETFs positioned on Zealand Pharma A/S

Name	Weight	AuM	1st Jan change
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0%	59 M€	+1.26%	-
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD	-0%	27 M€	0.00%	-

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

385

Sector

Biotechnology & Medical Research

Calendar

08-14 - Q2 2025 Earnings Release

More about the company